QIAGEN acquire OmicSoft Corporation
QIAGEN announced the acquisition of OmicSoft Corporation, providing access to OmicSoft’s powerful multi-omics data management infrastructure solution as well as ‘omics’ data sets that complement QIAGEN’s bioinformatics portfolio.
OmicSoft is recognized for its suite of software solutions that enable scientists and researchers to efficiently analyse and visualize their own data sets and compare them to massive volumes of publicly available ‘omics’ data sets and share results with colleagues. These solutions, which integrate enterprise access and cloud-based resources, are essential in addressing the rapidly growing need of researchers in discovery and translational research to manage, compare and share the massive volumes of data on DNA, RNA and other biological variables generated with next-generation sequencing (NGS) technologies.
OmicSoft is expected to enhance QIAGEN’s bioinformatics portfolio by adding key features for the management, analysis and sharing of both primary data and analyzed results, while also expanding the range of QIAGEN’s translational and clinical applications.
Through the addition of OmicSoft, QIAGEN will now offer solutions across the full spectrum of data management and interpretation needs. Within these infrastructure solutions, OmicSoft adds the ability to mine curated ‘omics’ data for unpublished findings.
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Protein Target Identified That Could Prevent StrokesNews
Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.READ MORE